# Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

> **NCT07482787** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Paradigm Therapeutics** · enrollment: 80 (estimated)

## Conditions studied

- Epidermolysis Bullosa (EB)

## Interventions

- **DRUG:** SD-101 Dermal Cream (6%)
- **DRUG:** Vehicle (SD-101 0%)

## Key facts

- **NCT ID:** NCT07482787
- **Lead sponsor:** Paradigm Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-05-17
- **Final completion:** 2027-06-17
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482787, "Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07482787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*